Fresenius SE & Co. KGaA (ETR:FRE)

Market Cap	24.57B -6.2%
Revenue (ttm)	23.28B +3.4%
Net Income	1.52B +35.3%
EPS	2.70 +35.3%
Shares Out	563.24M
PE Ratio	15.72
Forward PE	11.38
Dividend	1.05 (2.35%)
Ex-Dividend Date	May 25, 2026

Volume	1,137,472
Open	43.45
Previous Close	43.63
Day's Range	42.10 - 43.73
52-Week Range	35.11 - 52.96
Beta	0.83
Analysts	Buy
Price Target	55.59 (+28.4%)
Earnings Date	Nov 4, 2026

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1912
• Employees: 178,486
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: FRE

Financial Performance

In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.

Analyst Summary

According to 14 analysts, the average rating for FRE stock is "Buy." The 12-month stock price target is €55.59, which is an increase of 28.40% from the latest price.

Price Target

€55.59

(28.40% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 7, 2026

Data Sources Report a data error